UWCCC Cancer Genetic and Epigenetic Mechanisms (GEM) Program Summary Co-Leaders: Emery Bresnick and Michael Newton PROJECT SUMMARY/ABSTRACT As genetic and epigenetic mechanisms underlie human cancer initiation and progression, components of these mechanisms represent extremely promising targets for cancer prevention, diagnosis, and therapy. Considering the multitude of regulatory factors involved, and the many unanswered mechanistic questions, our vision is that much of the mechanistic knowledge and druggable space remain to be discovered. Thus, from both fundamental and clinical/translational perspectives, elucidating cancer genetic and epigenetic mechanisms continues to hold great promise. The UWCCC Cancer Genetic and Epigenetic Mechanisms Program (GEM) consists of 27 highly collaborative members spanning 13 departments and 6 schools at UW-Madison. The program members include basic and translational scientists conducting multidisciplinary research, with 3 members directing clinical cancer research programs and engaged in patient care. Senior members actively mentor junior faculty, and additional faculty recruitments are ongoing. During the prior funding period, GEM members published 453 papers, many of which appeared in high-impact journals including Cancer Cell, Mol. Cell, Science, Science Trans. Med., Nature Chem. Biol., J. Clin. Invest., and Genome Res. The 27 GEM members brought in a total of $9.98 M in direct cost cancer-relevant funding for which they are the PI (NIH total, $5.79 M, of which NCI, $1.25 M). GEM Thematic Aims are: 1) Discover and elucidate cancer genetic mechanisms; and 2) Discover and elucidate cancer epigenetic mechanisms. Multidisciplinary GEM teams are analyzing genetic and epigenetic mechanisms in breast, prostate, sarcoma, myeloid leukemia, and other cancers. The discoveries are used to develop new paradigms in cancer biology, and via new intra- and inter- programmatic collaborations, are applied toward clinical trials to improve cancer prevention, diagnosis, and therapy. GEM-derived methodological/technological innovations continue to dramatically enable GEM and broader UWCCC cancer research. An overarching theme is our invention and deployment of powerful strategies to discover and elucidate cancer mechanisms and enable diagnostic and therapeutic modalities unlikely to emerge from existing paradigms.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
2P30CA014520-44
Application #
9490026
Study Section
Subcommittee I - Transistion to Independence (NCI)
Project Start
Project End
Budget Start
2018-05-30
Budget End
2019-03-31
Support Year
44
Fiscal Year
2018
Total Cost
Indirect Cost
Name
University of Wisconsin Madison
Department
Type
DUNS #
161202122
City
Madison
State
WI
Country
United States
Zip Code
53715
Elsaid, Mohamed Y; Shahi, Ankita; Wang, Albert R et al. (2018) Enhanced Radiosensitivity in Solid Tumors using a Tumor-selective Alkyl Phospholipid Ether Analog. Mol Cancer Ther 17:2320-2328
Dennison, Kirsten L; Chack, Aaron C; Hickman, Maureen Peters et al. (2018) Ept7, a quantitative trait locus that controls estrogen-induced pituitary lactotroph hyperplasia in rat, is orthologous to a locus in humans that has been associated with numerous cancer types and common diseases. PLoS One 13:e0204727
Zaitoun, Ismail S; Cikla, Ulas; Zafer, Dila et al. (2018) Attenuation of Retinal Vascular Development in Neonatal Mice Subjected to Hypoxic-Ischemic Encephalopathy. Sci Rep 8:9166
Hart, Vicki; Trentham-Dietz, Amy; Berkman, Amy et al. (2018) The association between post-diagnosis health behaviors and long-term quality of life in survivors of ductal carcinoma in situ: a population-based longitudinal cohort study. Qual Life Res 27:1237-1247
Lee, Hye Jin; Ehlerding, Emily B; Cai, Weibo (2018) Antibody-Based Tracers for PET/SPECT Imaging of Chronic Inflammatory Diseases. Chembiochem :
Albertini, Mark R; Yang, Richard K; Ranheim, Erik A et al. (2018) Pilot trial of the hu14.18-IL2 immunocytokine in patients with completely resectable recurrent stage III or stage IV melanoma. Cancer Immunol Immunother 67:1647-1658
Saghiri, Mohammad Ali; Asatourian, Armen; Nguyen, Eric H et al. (2018) Hydrogel Arrays and Choroidal Neovascularization Models for Evaluation of Angiogenic Activity of Vital Pulp Therapy Biomaterials. J Endod 44:773-779
Jamali, Nasim; Sorenson, Christine M; Sheibani, Nader (2018) Vitamin D and regulation of vascular cell function. Am J Physiol Heart Circ Physiol 314:H753-H765
Liu, Zhen; Ehlerding, Emily B; Cai, Weibo et al. (2018) One-step synthesis of an 18F-labeled boron-derived methionine analog: a substitute for 11C-methionine? Eur J Nucl Med Mol Imaging 45:582-584
Chakravarty, Rubel; Siamof, Cerise M; Dash, Ashutosh et al. (2018) Targeted ?-therapy of prostate cancer using radiolabeled PSMA inhibitors: a game changer in nuclear medicine. Am J Nucl Med Mol Imaging 8:247-267

Showing the most recent 10 out of 1528 publications